stockrow
Saturday 7 November 2026
Export GENB’s income statement to Excel — free account
Generate Biomedicines, Inc.
GENB Healthcare Biotechnology
Generate Biomedicines, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.9 million, up 55.9% from fiscal 2024.
13.06
0.49
+3.90%
Follow GENB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+2 more TTM periods Free account |
|
| (90.35%) | 0.00% | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(57.55%) | 0.00% | 0.00% | — | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(4.29) | (5.03) | 0.00 | 0.00 | |
Free Cash Flow |
(549.72) | (326.14) | (428.15) | — | |
Capital Expenditures |
(162.01) | 56.80 | (7.86) | — | |
| Other line items | |||||
Cash ROIC |
(60.09%) | (31.55%) | 109.44% | 0.00% | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
704.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
147.18% | — | — | — | |
Share Based Compensation of Revenue |
76.54% | — | — | — | |
Interest Coverage |
(241.14) | — | — | — | |
Operating CF/Net income |
1.53 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
0.69 | 0.67 | 0.87 | — | |
Capex/Depreciation |
(8.58) | 3.06 | (0.31) | — | |
Revenue per Share |
0.25 | 0.00 | — | 0.00 | |
Operating CF per Share |
(3.02) | (5.90) | 0.00 | 0.00 | |
Capex per Share |
(1.26) | 0.88 | 0.00 | 0.00 | |
Capex to Sales |
4.99 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026